Claims for Patent: 8,404,811

Summary for Patent: 8,404,811

Title:	Humanized anti-EGFL7 antibodies and methods using same
Abstract:	The present invention concerns antibodies to EGFL7 and the uses of same.
Inventor(s):	Ye; Weilan (Foster City, CA), Dennis; Mark (San Carlos, CA), Fredrickson; Jill (Sunnyvale, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	12/776,259
Patent Claims:	1. An isolated anti-EGFL7 antibody comprising a variable domain comprising the following HVR sequences: HVR-L1 comprising RTSQSLVHINXITYLH, wherein X is G or A (SEQ ID NO: 106, 241); HVR-L2 comprising RVSNRFS (SEQ ID NO: 101); HVR-L3 comprising GQSTHVPLT (SEQ ID NO: 131); HVR-H1 comprising GYTFIDYYMN (SEQ ID NO: 103); HVR-H2 comprising GDINLDNXGTHYNOKFKG (SEQ ID NO: 104, 242), wherein X is G or S; and HVR-H3 comprising AREGVYHDYDDYAMDY (SEQ ID NO: 105). 2. An isolated anti-EGFL7 antibody comprising a variable domain, wherein HVR-L1 comprises the amino acid sequence RTSQSLVHINAITYLH (SEQ ID NO: 241), HVR-L2 comprises the amino acid sequence RVSNRFS (SEQ ID NO: 101), HVR-L3 comprises the amino acid sequence GQSTHVPLT (SEQ ID NO: 131), HVR-H1 comprises the amino acid sequence GYTFIDYYMN (SEQ ID NO: 103), HVR-H2 comprises the amino acid sequence GDINLDNSGTHYNQKFKG (SEQ ID NO: 242), and HVR-H3 comprises the amino acid sequence AREGVYHDYDDYAMDY (SEQ ID NO: 105). 3. The antibody of claim 1 or 2, wherein the heavy chain comprises the following framework sequences: FR-H1 comprises EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 197); FR-H2 comprises WVRQAPGKGLEWX.sub.1, wherein X.sub.1 is I or V (SEQ ID NO: 228); FR-H3 comprises RX.sub.1TX.sub.2SX.sub.3DX.sub.4SX.sub.5X.sub.6TX.sub.7YX.sub.8QMNSLRAEDT- AVYYC, wherein X.sub.1 is F or V; X.sub.2 is I or L; X.sub.3 is selected from the group consisting of L, R, and V; X.sub.4 is K or N; X.sub.5 is selected from the group consisting of K, N, R, and S; X.sub.6 is N or S; X.sub.7 is selected from the group consisting of A, L, and V; and X.sub.8 is L or M (SEQ ID NO: 229); and FR-H4 comprises WGQGTLVTVSS (SEQ ID NO: 200). 4. The antibody of claim 3, wherein the heavy chain comprises the following framework sequences: FR-H1 comprises EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 197); FR-H2 comprises WVRQAPGKGLEWV (SEQ ID NO: 198); FR-H3 comprises RFTISRDX.sub.1SKNTX.sub.2YLQMNSLRAEDTAVYYCAR, wherein X.sub.1 is N or K; and X.sub.2 is selected from the group consisting of A, L, and V (SEQ ID NO: 230); and FR-H4 comprises WGQGTLVTVSS (SEQ ID NO: 200). 5. The antibody of claim 1 or 2, wherein the light chain comprises the following framework sequences: FR-L1 comprises DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 201), FR-L2 comprises WYQQKPGKAPKLLIY (SEQ ID NO: 202), FR-L3 comprises GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 203), FR-L4 comprises FGQGTKVEIK (SEQ ID NO: 221) or FGQGTKVEIKR (SEQ ID NO: 204). 6. The antibody of claim 1, wherein the light chain comprises the variable domain sequence of 18F7.v6 as shown in FIG. 27 (SEQ ID NO: 193). 7. The antibody of claim 1, wherein the light chain comprises the variable domain sequence of 18F7.v6k as shown in FIG. 27 (SEQ ID NO: 194). 8. The antibody of claim 1, wherein the heavy chain comprises the variable domain sequence of 18F7.v6 as shown in FIG. 28 (SEQ ID NO: 195). 9. The antibody of claim 1, wherein the heavy chain comprises the variable domain sequence of 18F7.v6k as shown in FIG. 28 (SEQ ID NO: 196). 10. The antibody of claim 1, wherein the light chain comprises the variable domain sequence of 18F7.v6 as shown in FIG. 27 (SEQ ID NO: 193) and the heavy chain comprises the variable domain sequence of 18F7.v6 as shown in FIG. 28 (SEQ ID NO: 195). 11. The antibody of claim 1, wherein the light chain comprises the variable domain sequence of 18F7.v6k as shown in FIG. 27 (SEQ ID NO: 194) and the heavy chain comprises the variable domain sequence of 18F7.v6k as shown in FIG. 28 (SEQ ID NO: 196). 12. The antibody of claim 1 or 2, wherein at least a portion of the framework sequence is a human consensus framework sequence. 13. The antibody of claim 12, comprising human is subgroup 1 consensus framework sequence. 14. The antibody of claim 12, comprising heavy chain human subgroup III consensus framework sequence. 15. The antibody of claim 1 or 2, wherein said antibody is a bispecific antibody. 16. The antibody of claim 15, wherein said bispecific antibody binds to vascular endothelial growth factor (VEGF). 17. The antibody of claim 16, where said bispecific antibody binds to the same VEGF epitope as bevacizumab or ranibizumab. 18. A composition comprising the antibody of claim 1. 19. The composition of claim 18, wherein the composition comprises a carrier. 20. The composition of claim 18 or 19, which is a pharmaceutical composition. 21. A composition comprising the antibody of claim 2. 22. The composition of claim 21, wherein the composition comprises a carrier. 23. The composition of claim 22, which is a pharmaceutical composition.

Details for Patent 8,404,811

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2039-02-26
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2039-02-26